HighTower Advisors LLC Has $1.25 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

HighTower Advisors LLC reduced its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 17.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 31,708 shares of the company's stock after selling 6,608 shares during the period. HighTower Advisors LLC's holdings in CRISPR Therapeutics were worth $1,248,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics during the third quarter worth $40,000. Highline Wealth Partners LLC acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at about $39,000. Western Pacific Wealth Management LP raised its stake in shares of CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after acquiring an additional 500 shares during the last quarter. Spire Wealth Management grew its stake in shares of CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after purchasing an additional 1,482 shares during the last quarter. Finally, MCF Advisors LLC acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $80,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,850 shares of the business's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now directly owns 77,530 shares of the company's stock, valued at $3,288,822.60. The trade was a 3.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Samarth Kulkarni sold 9,973 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $423,054.66. Following the completion of the transaction, the chief executive officer now owns 180,890 shares of the company's stock, valued at $7,673,353.80. The trade was a 5.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,381 shares of company stock valued at $1,608,243 in the last quarter. 4.10% of the stock is currently owned by insiders.

Remove Ads

CRISPR Therapeutics Stock Performance

NASDAQ CRSP traded down $1.05 on Friday, reaching $36.99. The company had a trading volume of 1,595,765 shares, compared to its average volume of 1,551,646. The company's fifty day moving average is $43.10 and its 200-day moving average is $45.17. The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of -8.46 and a beta of 1.77. CRISPR Therapeutics AG has a 1-year low of $36.52 and a 1-year high of $68.39.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Barclays increased their price objective on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. StockNews.com raised CRISPR Therapeutics to a "sell" rating in a report on Friday, March 21st. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 target price on the stock in a research note on Wednesday, February 12th. Citigroup dropped their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a research note on Tuesday, February 18th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.